10.1186/s12902-023-01497-x BMC Endocr Disord
Outcome information was collected by identifying all fracture-related diagnoses from index data onwards
ch mua hng uy tn ch lg u
Eur J Heart Fail 22:14951503 Seferovi PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, avuolu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferovi J, Jhund PS, Dattilo G, elutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainak M, Jankowska E, Mueller C, Cosentino F, Lund LH, Filippatos GS, Ruschitzka F, Coats AJS, Rosano GMC (2020) Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure
Recent studies have claimed clinical benefits in patients with heart and kidney failure, arthritis, and sleep apnea disorders, mediated in part through anti-inflammatory and metabolic pathways, with some benefits partly independent of the degree of weight loss achieved